Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunotherapy of Cancers Comes of Age Publisher Pubmed



Yousefi H1, 2 ; Yuan J3 ; Keshavarzfathi M1, 4, 5 ; Murphy JF6 ; Rezaei N1, 7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Endodontics, Dental Branch, Tehran Azad University, Tehran, Iran
  3. 3. Memorial Sloan Kettering Cancer Center, New York, NY, United States
  4. 4. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  5. 5. Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Charles River Laboratories, Wilmington, MA, United States
  7. 7. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Boston, MA, United States

Source: Expert Review of Clinical Immunology Published:2017


Abstract

Introduction: Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
2. Tumor Immunology, Clinical Immunology (2022)
3. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
4. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
5. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
6. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
7. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
8. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (65)
Hamid Reza Mirzaei (15)
Other Related Docs
9. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
10. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
11. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
12. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
13. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
14. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
15. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
16. Cell Transfer-Based Immunotherapies in Cancer: A Review, IUBMB Life (2020)
17. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
18. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
19. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
20. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
21. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
22. The Roles of Cd4+ T-Cells in Tumor Immunity, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
23. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
24. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
25. Adverse Events Following Administration of Anti-Ctla4 Antibody Ipilimumab, Frontiers in Oncology (2021)
26. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
27. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
28. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
29. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)
30. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
31. Construction and Functional Characterization of a Fully Human Anti-Cd19 Chimeric Antigen Receptor (Hucar)-Expressing Primary Human T Cells, Journal of Cellular Physiology (2019)
32. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
33. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
34. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
35. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
36. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
37. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
38. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
39. Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma, Expert Review of Anticancer Therapy (2015)
40. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
41. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
42. Introduction on Cancer Immunology and Immunotherapy, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
43. Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy, Pharmacological Research (2019)
44. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
45. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)
46. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
47. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
48. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)
49. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
50. Interferons: Role in Cancer Therapy, Immunotherapy (2020)